CDT
CDT Equity Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.63
−16.56%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +1560.0%
- EBIT
- +1034.2%
- EPS
- -84.5%
- Free cash flow
- +96.1%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +98.1%
- Free cash flow
- -84.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026